Popular weight-loss medications Wegovy and Mounjaro may come with serious digestive risks, according to a new study published in the Journal of the American Medical Association.
Key Findings
The research, conducted by academics in Taiwan and the US, analysed health records of approximately 16 million patients. It found that users of GLP-1 receptor agonists like semaglutide (Wegovy) and tirzepatide (Mounjaro) faced significantly higher risks of:
- Stomach paralysis (gastroparesis)
- Pancreatitis
- Bowel obstructions
How Significant Are the Risks?
While the absolute numbers remain relatively low, the study showed:
- 4x higher risk of pancreatitis
- 3.5x greater chance of bowel obstruction
- Increased likelihood of gastroparesis
Dr Mahyar Etminan, one of the study authors, emphasised: "These drugs are becoming increasingly popular, but patients and doctors need to be aware of these potentially serious side effects."
Industry Response
Manufacturers Novo Nordisk (Wegovy) and Eli Lilly (Mounjaro) maintain that gastrointestinal issues are known side effects already listed in medication guides. They stress that benefits outweigh risks for most patients when used as prescribed.
The NHS has approved Wegovy for weight management in certain obese patients, while Mounjaro awaits UK approval despite being available privately.
Expert Recommendations
Medical professionals advise:
- Discuss all risks with your doctor before starting treatment
- Monitor for symptoms like persistent nausea or abdominal pain
- Consider these drugs as part of comprehensive weight management
As demand for these medications grows, researchers call for further studies to better understand long-term effects.
